Disagreements between sponsors and FDA in scientific interpretation of clinical data often get only a one-sided treatment in public discussions. With the agency generally precluded from disclosing information about pending INDs or NDAs, it is at sponsors’ discretion to publicly reveal any details about FDA concerns with their applications.
One exception to the non-disclosure restrictions on the agency, however, is the advisory committee process.